SANDOSTATIN LAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sandostatin Lar, and what generic alternatives are available?
Sandostatin Lar is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in SANDOSTATIN LAR is octreotide acetate. There are twenty drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the octreotide acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sandostatin Lar
A generic version of SANDOSTATIN LAR was approved as octreotide acetate by WEST-WARD PHARMS INT on April 8th, 2005.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SANDOSTATIN LAR?
- What are the global sales for SANDOSTATIN LAR?
- What is Average Wholesale Price for SANDOSTATIN LAR?
Summary for SANDOSTATIN LAR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 29 |
| Clinical Trials: | 79 |
| Drug Prices: | Drug price information for SANDOSTATIN LAR |
| DailyMed Link: | SANDOSTATIN LAR at DailyMed |
Recent Clinical Trials for SANDOSTATIN LAR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | PHASE2 |
| Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 |
| ZonMw: The Netherlands Organisation for Health Research and Development | Phase 4 |
US Patents and Regulatory Information for SANDOSTATIN LAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-003 | Nov 25, 1998 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SANDOSTATIN LAR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-003 | Nov 25, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-001 | Nov 25, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-002 | Nov 25, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| Novartis | SANDOSTATIN LAR | octreotide acetate | INJECTABLE;INJECTION | 021008-003 | Nov 25, 1998 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SANDOSTATIN LAR
See the table below for patents covering SANDOSTATIN LAR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 2512 | ⤷ Start Trial | |
| Australia | 543198 | ⤷ Start Trial | |
| Australia | 6468880 | ⤷ Start Trial | |
| Canada | 1182109 | POLYPEPTIDES, PROCEDE DE PRODUCTION, COMPOSES PHARMACEUTIQUES LES CONTENANT ET APPLICATIONS (POLYPEPTIDES, PROCESSES FOR THEIR PRODUCTION, PHARMACEUTICAL COMPOSITIONS COMPRISING SAID POLYPEPTIDES AND THEIR USE) | ⤷ Start Trial |
| Czechoslovakia | 228140 | PRODUCTION OF STRAIGHT OR MONOCYCLIC POLYPEPTIDES | ⤷ Start Trial |
| Cyprus | 1327 | NOVEL POLYPEPTIDES,PROCESSES FOR THEIR PRODUCTION,PHARMACEUTICAL COMPOSITIONS COMPRISING SAID POLYPEPTIDES AND THEIR USE | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SANDOSTATIN LAR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0029579 | SPC/GB93/097 | United Kingdom | ⤷ Start Trial | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch